Abstract
We report here a new class of compounds, quinoline derivatives, as potential inhibitors of in vitro bovine serum albumin-methylglyoxal glycation. Among compounds 1-19, compound 14 was found to be the most active analog with IC50 of 282.98 ± 8.4 µM. Compounds 12 (IC50 = 661.78 ± 8.7 µM) and 15 (IC50 = 629.43 ± 7.85 7 µM) were also identified as modest inhibitors, in comparison to the standard inhibitor, rutin (IC50 = 294.50 ± 1.5 µM). When evaluated for antioxidant activity through in vitro DPPH radical scavenging assay, compounds 3 (IC50 = 2.19 ± 0.27 µM), 6 (IC50 = 7.35 ± 2.27 µM), 11 (IC50 = 8.96 ± 0.56 µM), and 12 (IC50 = 10.11 ± 2.03 µM), and 15 (IC50 = 7.01 ± 3.87 µM) were found to be more active than the standard i.e. gallic acid (IC50 = 23.34 ± 0.43 µM). These compounds were also evaluated for cytotoxicity against rat fibroblast cell line (3T3 cell line). All compounds were found to be non-toxic in cellular model. This study identifies quinoline derivatives as a new class of inhibitors of protein glycation in vitro, along with antioxidant and non-toxic nature. These properties make them interesting leads for further studies as potential anti-diabetic agents.
Keywords: Advanced glycation end products (AGEs), antioxidant, diabetes, glycation inhibitors, quinoline, reactive oxygen species.
Medicinal Chemistry
Title:Antiglycation Activity of Quinoline Derivatives- A New Therapeutic Class for the Management of Type 2 Diabetes Complications
Volume: 11 Issue: 1
Author(s): Bilquees Bano, Sanaullah Abbasi, Jalaluddin A. J. Khan, Shafqat Hussain, Saima Rasheed, Shahnaz Perveen, Khalid Mohammed Khan and M. Iqbal Choudhary
Affiliation:
Keywords: Advanced glycation end products (AGEs), antioxidant, diabetes, glycation inhibitors, quinoline, reactive oxygen species.
Abstract: We report here a new class of compounds, quinoline derivatives, as potential inhibitors of in vitro bovine serum albumin-methylglyoxal glycation. Among compounds 1-19, compound 14 was found to be the most active analog with IC50 of 282.98 ± 8.4 µM. Compounds 12 (IC50 = 661.78 ± 8.7 µM) and 15 (IC50 = 629.43 ± 7.85 7 µM) were also identified as modest inhibitors, in comparison to the standard inhibitor, rutin (IC50 = 294.50 ± 1.5 µM). When evaluated for antioxidant activity through in vitro DPPH radical scavenging assay, compounds 3 (IC50 = 2.19 ± 0.27 µM), 6 (IC50 = 7.35 ± 2.27 µM), 11 (IC50 = 8.96 ± 0.56 µM), and 12 (IC50 = 10.11 ± 2.03 µM), and 15 (IC50 = 7.01 ± 3.87 µM) were found to be more active than the standard i.e. gallic acid (IC50 = 23.34 ± 0.43 µM). These compounds were also evaluated for cytotoxicity against rat fibroblast cell line (3T3 cell line). All compounds were found to be non-toxic in cellular model. This study identifies quinoline derivatives as a new class of inhibitors of protein glycation in vitro, along with antioxidant and non-toxic nature. These properties make them interesting leads for further studies as potential anti-diabetic agents.
Export Options
About this article
Cite this article as:
Bano Bilquees, Abbasi Sanaullah, Khan A. J. Jalaluddin, Hussain Shafqat, Rasheed Saima, Perveen Shahnaz, Khan Mohammed Khalid and Choudhary Iqbal M., Antiglycation Activity of Quinoline Derivatives- A New Therapeutic Class for the Management of Type 2 Diabetes Complications, Medicinal Chemistry 2015; 11 (1) . https://dx.doi.org/10.2174/1573406410666140526151254
DOI https://dx.doi.org/10.2174/1573406410666140526151254 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety The Emerging Roles of Leptin and Ghrelin in Cardiovascular Physiology and Pathophysiology
Current Vascular Pharmacology Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Current Alzheimer Research The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Low Molecular Weight Compounds with Transition Metals as Free Radical Scavengers and Novel Therapeutic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development)
Current Pharmaceutical Design